ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company’s TAP Technology - Yahoo Finance

Of particular note, the findings in the trastuzumab emtansine EMILIA Phase III trial will be featured in an ASCO plenary session on June 3, and findings with SAR3419 administered with its Phase II dosing schedule will be reported in a poster ...

Crossing Boundaries in Molecular Therapy: HER2 in ALL - Medscape News

[1] In this study, a small group of patients with refractory and relapsed HER2-positive adult B-cell acute lymphocytic leukemia (ALL) were treated with trastuzumab, a well-established drug in the management of breast cancer and, more recently ...

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec - News-Medical.Net

Starting with the recent launch of fully human, recombinant antibodies binding Rituximab (Rituxan ®) and Trastuzumab (Herceptin ®), AbD Serotec plans to expand this product category with antibodies against Alemtuzumab (Campath ®), Bevacizumab ...

ASCO Preview: Eight Cancer Drugs to Watch at the Big Show - Xconomy

Evidence has been mounting for years that this “souped-up” antibody drug could be much more potent than Genentech’s original trastuzumab (Herceptin), the pioneering breast cancer medicine that’s almost 15 years old. Now the South San ...

Generex Augments Antigen Express Scientific Advisory Board - Marketwatch

He has been a leader in the development of the antibody-drug conjugate trastuzumab-DM1 (T-DM1). He has led several biopsy intensive preoperative clinical trials of trastuzumab and bevacizumab based therapies with the goal of identifying ...

Heart Failure in a Breast Cancer Survivor - Medscape News

The oncologist recommended four cycles of doxorubicin plus cyclophosphamide. Final trials for trastuzumab in the adjuvant setting had not been completed at the time of the consultation. And, because of the small size of the primary tumor (0.8 cm ...

Galena Biopharma With Near Term ASCO Catalyst - Seekingalpha.com

5. Plenty of upcoming milestones During H1 2012, the company will commence a Phase II trial comparing NeuVax in combination with Herceptin (trastuzumab) versus trastuzumab alone, in a 300-patient, randomized study in the adjuvant breast cancer setting.

Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through ‘Precision Medicine’ - Newswise

This will also lead us to a better understanding in diagnosing disease and providing a prognosis.” The breast cancer drug trastuzumab is one example of how genomic information is helping to drive targeted cancer therapies. Study has shown that ...

Genentech To Present New Data On Important Progress For Advanced Cancer Patients - NASDAQ

Trastuzumab emtansine's pivotal Phase III data in people with HER2-positive metastatic breast cancer who had previously received treatment with Herceptin and a taxane (chemotherapy) will be presented for the first time. These data will be ...